Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exelixis, a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for cancer treatment, has updated interim data of an ongoing phase 2 adaptive randomized discontinuation trial evaluating the effects of cabozantinib (XL184) treatment in patients with metastatic castration-resistant prostate cancer (CRPC).
Subscribe to our email newsletter
Cabozantinib is an inhibitor of tumor growth, metastasis and angiogenesis. It simultaneously targets MET and VEGFR2 – key kinases involved in the development and progression of many cancers.
Resultant data supports the findings that cabozantinib reduces or stabilizes metastatic bone lesions in nearly all patients, reduces bone pain and narcotic analgesic medication, shows high rates of complete or partial bone scan resolution (85%), and increases hemoglobin in anemic patients.
Cabozantinib has also shown encouraging early signals of durable clinical benefit in docetaxel-naïve and pretreated patients.
University of Michigan Departments of Internal Medicine and Urology professor David Smith said cabozantinib may offer a unique approach to the treatment of prostate cancer, particularly due to its effect on metastatic bone lesions.
Smith presented the data in a poster session at the American Society of Clinical Oncology’s 2011 Genitourinary Cancers Symposium in Orlando, Florida on 17 February.